天津泰达生物医学工程股份有限公司（股票代码：08189）于2026年4月1日发布3月股份变动月报表，报告期截至2026年3月31日。根据公告披露，公司当月各类股份及注册股本均无新增发行或注销情况。
截至本报告期末，普通股H股保持在1,436,400,000股，内资股则维持在697,500,000股，二者对应的注册股本不变，分别为人民币143,640,000元和人民币69,750,000元，合计注册资本为人民币213,390,000元。公司同时确认当月无回购或库藏股行动，也未发生任何股份期权、权证或可换股票据的变动。
公司在公告中声明，已遵守香港联合交易所有限公司《上市规则》及其他相关法律规定，并由董事孙莉签署确认。综上所述，截至3月31日，泰达生物股本结构保持稳定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.